Literature DB >> 8436163

Acute effects of cicletanine in angina pectoris.

D L Murdoch1, E Henderson, H J Dargie, G T McInnes.   

Abstract

The anti-anginal properties of single doses of a new anti-hypertensive drug, cicletanine, were investigated in a double-blind, randomised, balanced, crossover comparison with placebo in sixteen patients with chronic stable angina pectoris. All subjects underwent treadmill exercise 2 h after drug administration and 24 h ambulatory ECG monitoring with ST scanning. Although there were significantly fewer episodes of ST depression on ambulatory monitoring after cicletanine, total exercise duration and time to 1 mm ST depression were unchanged. This report provides little evidence of an acute anti-anginal effect of cicletanine but longer term studies may be indicated to further evaluate this drug's potential role in the management of angina pectoris.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8436163     DOI: 10.1007/bf00315287

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  THE TWO-PERIOD CHANGE-OVER DESIGN AN ITS USE IN CLINICAL TRIALS.

Authors:  J E GRIZZLE
Journal:  Biometrics       Date:  1965-06       Impact factor: 2.571

2.  Using baseline measurements in the two-period crossover clinical trial.

Authors:  A R Willan; J L Pater
Journal:  Control Clin Trials       Date:  1986-12

3.  Competitive and stereoselective histamine H1 antagonistic effect of cicletanide in guinea-pig isolated ileum.

Authors:  P Schoeffter; J Ghysel-Burton; M Cabanie; T Godfraind
Journal:  Eur J Pharmacol       Date:  1987-04-14       Impact factor: 4.432

4.  Comparison of cicletanine with other antihypertensive drugs in SHR-SP models.

Authors:  E Malherbe; M Le Hegarat; F Clostre; P Braquet
Journal:  Drugs Exp Clin Res       Date:  1988

5.  Activation of prostacyclin synthesis in cultured aortic smooth muscle cells by 'diuretic-antihypertensive' drugs.

Authors:  B Dorian; J Larrue; F V Defeudis; H Salari; P Borgeat; P Braquet
Journal:  Biochem Pharmacol       Date:  1984-07-15       Impact factor: 5.858

6.  Adjusting for baseline measurements in the two-period crossover study: a cautionary note.

Authors:  J L Fleiss; S Wallenstein; R Rosenfeld
Journal:  Control Clin Trials       Date:  1985-09

7.  Exposing patients with chronic, stable, exertional angina to placebo periods in drug trials.

Authors:  S P Glasser; P I Clark; R J Lipicky; J M Hubbard; S Yusuf
Journal:  JAMA       Date:  1991-03-27       Impact factor: 56.272

8.  Effects of cicletanine in the left circumflex coronary artery occlusion-reperfusion canine model of sudden death: analysis of 107 experiments using Cox's proportional hazards model.

Authors:  R Jouve; P E Puddu; F Langlet; M Lanti; J C Guillen; P H Rolland; A Serradimigni
Journal:  Drugs Exp Clin Res       Date:  1988

9.  Effects of diltiazem-induced calcium blockade upon exercise capacity in effort angina due to chronic coronary artery disease.

Authors:  R I Low; P Takeda; G Lee; D T Mason; N A Awan; A N DeMaria
Journal:  Am Heart J       Date:  1981-06       Impact factor: 4.749

10.  Determination of the optimal dose of the antihypertensive drug cicletanine hydrochloride in man.

Authors:  P Guinot; J Jewitt-Harris; T Tarrade
Journal:  Arzneimittelforschung       Date:  1989-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.